[go: up one dir, main page]

IL197262A0 - Anti cancer use of caffeic acid and its derivatives - Google Patents

Anti cancer use of caffeic acid and its derivatives

Info

Publication number
IL197262A0
IL197262A0 IL197262A IL19726209A IL197262A0 IL 197262 A0 IL197262 A0 IL 197262A0 IL 197262 A IL197262 A IL 197262A IL 19726209 A IL19726209 A IL 19726209A IL 197262 A0 IL197262 A0 IL 197262A0
Authority
IL
Israel
Prior art keywords
treatment
gleevec
resistant
present
caffeic acid
Prior art date
Application number
IL197262A
Original Assignee
Kalpana Sanjay Joshi
Piramal Life Sciences Ltd
Sivakumar Meenakshi
Aware Valmik Sopan
Wagh Vilas
Deshpande Amit
Sarde Ankush Gangaram
Sharma Somesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalpana Sanjay Joshi, Piramal Life Sciences Ltd, Sivakumar Meenakshi, Aware Valmik Sopan, Wagh Vilas, Deshpande Amit, Sarde Ankush Gangaram, Sharma Somesh filed Critical Kalpana Sanjay Joshi
Publication of IL197262A0 publication Critical patent/IL197262A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) wherein X is O, NH, or heterocyclyl; R may be present or absent and if present, is H, alkyl, aryl, or heterocyclyl; in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with GLEEVEC. The invention also relates to a method for reducing the proliferation of cells that are resistant to GLEEVEC by contacting the cells with a compound of general formula (1). The present invention also relates to pharmaceutical compositions (for the manufacture of the medicament) including caffeic acid or a derivative or a salt thereof represented by the general formula (1) for the treatment of chronic myeloid leukemia (CML) that is resistant to treatment with GLEEVEC, or for reducing the proliferation of cells that are resistant to GLEEVEC. The present invention further relates to a method of treatment of chronic myeloid leukemia (CML) that is resistant to treatment with GLEEVEC.
IL197262A 2006-09-01 2009-02-25 Anti cancer use of caffeic acid and its derivatives IL197262A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01
PCT/IB2007/053308 WO2008026125A2 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and derivatives

Publications (1)

Publication Number Publication Date
IL197262A0 true IL197262A0 (en) 2009-12-24

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197262A IL197262A0 (en) 2006-09-01 2009-02-25 Anti cancer use of caffeic acid and its derivatives

Country Status (12)

Country Link
US (1) US20100010002A1 (en)
EP (1) EP2061452B1 (en)
JP (1) JP2010502586A (en)
AT (1) ATE530176T1 (en)
AU (1) AU2007290960B2 (en)
CA (1) CA2662126A1 (en)
DK (1) DK2061452T3 (en)
ES (1) ES2376277T3 (en)
IL (1) IL197262A0 (en)
PT (1) PT2061452E (en)
TW (1) TW200812955A (en)
WO (1) WO2008026125A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373656A1 (en) * 2008-11-07 2011-10-12 Council Of Scientific & Industrial Research Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (en) * 2008-12-17 2011-02-02 中南大学 Specificity inhibitor of leukaemia bcr/abl fusion gene mRNA
ES2575100T3 (en) 2009-05-04 2016-06-24 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
KR20130010895A (en) * 2010-02-25 2013-01-29 피라말 엔터프라이지즈 리미티드 Oxadiazole compounds, their preparation and use
EA030038B1 (en) 2010-10-27 2018-06-29 Прометик Фарма Смт Лимитед USE OF COMPOUNDS FOR TREATMENT OF CANCER AND METHOD FOR TREATMENT OF CANCER
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
WO2014190035A2 (en) * 2013-05-21 2014-11-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using histone h3k27me2 biomarkers and modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
EP4031123A1 (en) * 2019-09-17 2022-07-27 Enzene Biosciences Limited Compositions for use in inhibiting src kinase and treating and preventing associated disorders
JP2022104792A (en) 2020-12-29 2022-07-11 ヒュサイオン カンパニー リミテッド Piperlongumine-based compound and immunoregulator comprising the same
EP4277896A4 (en) * 2021-01-14 2025-03-05 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Anti-quorum sensing, anti-biofilm, and inflammation attenuating compounds, compositions, and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
AU2002348746A1 (en) * 2002-05-31 2003-12-19 Council Of Scientific And Industrial Research A herbal molecule as potential anti-leukemic drug
EP1524973A1 (en) * 2002-07-08 2005-04-27 Council of Scientific and Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Also Published As

Publication number Publication date
US20100010002A1 (en) 2010-01-14
TW200812955A (en) 2008-03-16
JP2010502586A (en) 2010-01-28
EP2061452B1 (en) 2011-10-26
DK2061452T3 (en) 2012-02-13
EP2061452A2 (en) 2009-05-27
ES2376277T3 (en) 2012-03-12
ATE530176T1 (en) 2011-11-15
WO2008026125A2 (en) 2008-03-06
AU2007290960A1 (en) 2008-03-06
PT2061452E (en) 2012-01-13
WO2008026125A3 (en) 2008-10-02
CA2662126A1 (en) 2008-03-06
AU2007290960B2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
IL197262A0 (en) Anti cancer use of caffeic acid and its derivatives
TW200833675A (en) Nicotinamide derivatives
UA94606C2 (en) 2-thioxanthine derivatives, composition containing the compound and the use thereof in therapy
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
TN2009000084A1 (en) Adenosine derivatives as a2a receptor agonists
MX2010007375A (en) Novel lupane derivatives.
TW200728307A (en) Novel spirochromanone derivatives
NO2016021I1 (en) 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
MXPA06013164A (en) Pyrimidines derivatives for the treatment of abnormal cell growth.
MX2009012847A (en) Dipeptide analogs as coagulation factor inhibitors.
MY177111A (en) Substituted amide derivatives and methods of use
MX2013011589A (en) Methods and compositions for treating parkinson's disease.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
UA89123C2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TN2010000038A1 (en) Organic compounds
MX341341B (en) Benzamide derivatives and their use as hsp90 inhibtors.
MX2008016358A (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors.
MX2007013624A (en) Protein kinase inhibitors.
MX2009007038A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders.
MX2009003728A (en) New isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities.
MY150468A (en) Quinolinone derivatives and their pharmaceutical compositions
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents